RT Journal Article
SR Electronic
T1 694 A randomized phase II clinical trial of SBRT and pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c(BDCA-1)<sup>+</sup>/CD141(BDCA-3)<sup>+</sup> myeloid dendritic cells in solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A786
OP A786
DO 10.1136/jitc-2023-SITC2023.0694
VO 11
IS Suppl 1
A1 Vounckx, Manon
A1 Tijtgat, Jens
A1 Dirven, Iris
A1 Vandenbroucke, Frederik
A1 Raemaeckers, Steven
A1 Ilsen, Bart
A1 Mustapha, Selma Ben
A1 Loon, Jens Van
A1 Stevens, Latoya
A1 Geeraerts, Xenia
A1 Riet, Ivan Van
A1 Dufait, Ines
A1 Tuyaerts, Sandra
A1 Decoster, Lore
A1 Ridder, Mark De
A1 Neyns, Bart
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A786.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.